Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion

General Hospital Psychiatry

Volumn 30, Issue 4, 2008, Pages 372-377

  Levin, Tomer T ^a   Cortes Ladino, Alberto ^a   Weiss, Mark ^a   Palomba, M Lia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Citalopram; Delirium; Drug interaction; Fluconazole; Serotonin toxicity

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANOREXIGENIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BUSPIRONE; CARDIOVASCULAR AGENT; CITALOPRAM; CLARITHROMYCIN; CLONAZEPAM; DELAVIRDINE; FLUCONAZOLE; FLUVOXAMINE; IMATINIB; ISONIAZID; KETANSERIN; LORAZEPAM; METHYLENE BLUE; NARCOTIC AGENT; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENYTOIN; PROTON PUMP INHIBITOR; RITONAVIR; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE;

ADULT; AGED; ARTICLE; CARCINOID SYNDROME; CASE REPORT; CONFUSION; DELIRIUM; DEPRESSION; DISEASE DURATION; DISORIENTATION; DRUG FEVER; DRUG INHIBITION; DRUG METABOLISM; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; INFORMATION RETRIEVAL; LONG TERM MEMORY; LOW DRUG DOSE; MEDLINE; NONHUMAN; PERSEVERATION; SEIZURE; SEROTONIN SYNDROME; SHORT TERM MEMORY; SOMNOLENCE; TREATMENT RESPONSE;

AGED; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; CYPROHEPTADINE; DELIRIUM; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FEMALE; FLUCONAZOLE; HUMANS; MIDDLE AGED; SEROTONIN ANTAGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 45549088131     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2008.03.008     Document Type: Article

References (29)

1. Breitbart W., et al. The memorial delirium assessment scale. J Pain Symptom Manage 13 3 (1997) 128-137
2. Alici-Evcimen Y., and Breitbart W.S. Ifosfamide neuropsychiatric toxicity in patients with cancer. Psychooncology (2007)
3. Gillman P.K. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 59 11 (2006) 1046-1051
4. Boyer E.W., and Shannon M. The serotonin syndrome. N Engl J Med 352 11 (2005) 1112-1120
5. Evans C.E., and Sebastian J. Serotonin syndrome. Emerg Med J 24 4 (2007)
6. Silins E., Copeland J., and Dillon P. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Australian and New Zealand. J Psychiatry 41 8 (2007) 649-655
7. Nelson L.S., et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 45 (2007) 315-332
8. Nemeroff C.B., Preskorn S.H., and Devane C.L. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr 12 5 Suppl 7 (2007) 1-13
9. Huska M.T., Catalano G., and Catalano M.C. Serotonin syndrome associated with the use of escitalopram. CNS Spectr 12 4 (2007) 270-274
10. Altman E.M., and Manos G.H. Serotonin syndrome associated with citalopram and meperidine. Psychosomatics 48 4 (2007) 361-363
11. Tseng W.P., et al. Citalopram-induced serotonin syndrome: a case report. Gaoxiong Yi Xue Ke Xue Za Zhi 21 7 (2005) 326-328
12. Mahlberg R., et al. Serotonin syndrome with tramadol and citalopram. Am J Psychiatry 161 6 (2004) 1129
13. Bernard L., et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 36 9 (2003) 1197
14. Lexi-Interact (2007), Lexi-Comp, Inc, Hudson (Ohio)
15. In: DeVane C.L., Schatzberg A.F., and Nemeroff C.B. (Eds). Principles of pharmacokinetics and pharmacodynamics. 3rd ed. (2004), The American Psychiatric Publishing Textbook of Psychopharmacology 129-145
16. Nisijima K., et al. Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 37 2 (2004) 57-62
17. Nijisima K., et al. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 43 (2003) 155-164
18. Nisijima K., et al. Potent serotonin receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5HT syndrome. Brain Res 890 (2001) 23-31
19. Shioda K., et al. Extracellular serotonin, dopamine, and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 633-640
20. Sternbach H. Serotonin syndrome: how to avoid, identify, and treat dangerous drug interactions. Curr Psychiatry 5 (2003) 15-24
21. Prator B.C. Serotonin syndrome. J Neurosci Nurs 38 2 (2006) 102-104
22. Graudins A., Stearman A., and Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 16 4 (1998) 615-619
23. Jones D., and Story D. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care 33 2 (2005) 181-187
24. Brown T.M. Nitroglycerin in the treatment of the serotonin syndrome (letter). Am J Emerg Med 22 6 (2004) 510
25. Haslett C.D., and Kumar S. Can olanzapine be implicated in causing serotonin syndrome?. Psychiatry Clin Neurosci 56 5 (2002) 533-535
26. Reeves R.R., Mack J.E., and Beddingfield J.J. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 36 3 (2002) 440-443
27. Karki S.D., and Masood G.R. Combination risperidone and SSRI-induced serotonin syndrome. Ann Pharmacother 37 3 (2003) 388-391
28. Kapur S., et al. Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry 154 6 (1997) 884
29. BrintzenhofeSzoc K., et al. Mixed anxiety-depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics (2008) [In press]